MIRATI THERAPEUTICS INC's ticker is MRTX and the CUSIP is 60468T105. A total of 208 filers reported holding MIRATI THERAPEUTICS INC in Q2 2023. The put-call ratio across all filers is 0.22 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,159,001 | -92.1% | 26,607 | -93.4% | 0.01% | -91.3% |
| Q2 2023 | $14,670,045 | -41.9% | 406,035 | -40.2% | 0.07% | -44.8% |
| Q1 2023 | $25,232,504 | +260.2% | 678,658 | +338.9% | 0.12% | +220.5% |
| Q4 2022 | $7,005,832 | +313.6% | 154,620 | +537.4% | 0.04% | +333.3% |
| Q3 2022 | $1,694,000 | -93.7% | 24,257 | -93.9% | 0.01% | -93.5% |
| Q2 2022 | $26,864,000 | +441.0% | 400,180 | +562.6% | 0.14% | +396.4% |
| Q1 2022 | $4,966,000 | +564.8% | 60,399 | +1206.8% | 0.03% | +460.0% |
| Q2 2021 | $747,000 | -81.9% | 4,622 | -80.8% | 0.01% | -83.3% |
| Q1 2021 | $4,131,000 | +32.7% | 24,118 | +70.2% | 0.03% | +15.4% |
| Q4 2020 | $3,112,000 | +55.6% | 14,170 | +17.6% | 0.03% | +52.9% |
| Q3 2020 | $2,000,000 | -33.2% | 12,047 | -58.6% | 0.02% | -79.5% |
| Q2 2019 | $2,994,000 | +13.5% | 29,071 | -19.2% | 0.08% | +5.1% |
| Q1 2019 | $2,637,000 | – | 35,977 | – | 0.08% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aviva Holdings Ltd. | 3,135,966 | $136,602,679 | 87.83% |
| EcoR1 Capital, LLC | 5,748,399 | $250,400,260 | 8.45% |
| Boxer Capital, LLC | 3,201,440 | $139,454,726 | 7.42% |
| RTW INVESTMENTS, LP | 6,768,514 | $294,836,470 | 6.22% |
| Paradigm Biocapital Advisors LP | 1,668,116 | $72,663,133 | 4.93% |
| Avoro Capital Advisors LLC | 6,666,666 | $290,399,971 | 4.53% |
| Octagon Capital Advisors LP | 655,051 | $28,534,022 | 4.38% |
| Artal Group S.A. | 2,024,226 | $88,175 | 3.78% |
| Ally Bridge Group (NY) LLC | 70,283 | $3,061,527 | 3.59% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 216,000 | $9,404,640 | 3.17% |